Chelsea therapeutics celebrates positive Phase III Northera results
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics' Northera (droxidopa) met its primary endpoint in a second pivotal trial for neurogenic orthostatic hypotension (NOH), providing relief for the company after an earlier Phase III failed. The progress is particularly welcome in light of the faltering of Shire's ProAmatine (midodrine): ProAmatine is approved in the US for NOH, but the FDA is currently considering rescinding approval due to a lack of efficacy data. The top-line data sent Chelsea shares up around 40% between 17 and 20 September, to settle at $5.73 on Nasdaq.